Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
Publication with shared reference
10.1016/j.radonc.2026.111479
Home
Publications
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
Publication with shared reference
10.1016/j.radonc.2026.111479
Publications with shared reference:
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
0
publications found
Export
Export
Analytics view
Analytics view
Scroll to top